TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33978745
Drug: Zoledronate infusion
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronate infusion after denosumab treatment (> 6 Group)
Study: 33978745
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of denosumab treatment duration with LS-BMD change
Study: 33891348
Drug: Fremanezumab quarterly
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fremanezumab quarterly (675 mg)
Study: 32958075
Drug: Fremanezumab monthly
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fremanezumab monthly (675 mg)
Study: 33477404
Drug: Tocotrienol-rich vitamin
Normalized name: tocotrienols / vitamin E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocotrienol-rich vitamin E (Tocovid SupraBioTM; Hovid Berhad, Ipoh, Malaysia) 400 mg daily
Study: 34120417
Drug: 1% prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% prednisolone acetate eye drops in tapering doses for 4 weeks
Study: 32610257
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1000 mg/d)
Study: 35835336
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with mitomycin C (MMC, 0.4 mg/ml for 2 minutes)
Study: 35544780
Drug: Standard sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sterile gauze dressing (control group, n = 16), changed after 24 to 48 hours and replaced daily for 5 days.
Study: 39147573
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment alone
Study: 34483297
Drug: Combination cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination cognitive behavioral therapy and medication management algorithm (COMB‐R)
Study: 34348189
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy technique (CT)
Study: 32133164
Drug: IYCF +
Approvals — FDA: no, EMA: no, PMDA: no
Description: IYCF + WASH (20g small-quantity lipid-based nutrient supplement/day from 6 to 18 months, complementary feeding counselling, pit latrine, 2 hand-washing stations, liquid soap, chlorine, play space, hygiene counselling)
Study: 32332930
Drug: Genotype-based warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-based warfarin dosing
Study: 32332930
Drug: Standard warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard warfarin dosing
Study: 32326325
Drug: P2Y12 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P2Y12 inhibitors (Ticagrelor and Clopidogrel)
Study: 33070009
Drug: Buspirone (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (7.5 mg twice daily, titrated to maximum 30 mg twice daily)
Study: 35921450
Drug: Cinpanemab 250
Normalized name: Cinpanemab
DrugBank: Cinpanemab (DB16127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinpanemab 250 mg
Study: 35921450
Drug: Cinpanemab 1250
Normalized name: Cinpanemab
DrugBank: Cinpanemab (DB16127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinpanemab 1250 mg
Study: 35921450
Drug: Cinpanemab 3500
Normalized name: Cinpanemab
DrugBank: Cinpanemab (DB16127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinpanemab 3500 mg
Study: 32636281
Drug: Optimised background
Normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised background therapy (OBT) plus maraviroc (MVC)
Study: 32636281
Drug: Optimised background
Normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised background therapy (OBT) alone
Study: 33785651
Drug: Venetoclax tablets
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax tablets
Study: 32614368
Drug: Lidocaine (L‐SLNB)
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine (L‐SLNB)
Study: 33998885
Drug: Cannabidivarin (CBDV)
Normalized name: Cannabidivarin
DrugBank: Cannabidivarin (DB14050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabidivarin (CBDV) 800 mg twice daily (b.i.d.)
Study: 32356586
Drug: Oral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate (MTX) plus narrowband ultraviolet light B (NB‐UVB) phototherapy, 10 mg oral MTX weekly and NB‐UVB sessions twice weekly for 12 weeks
Study: 32356586
Drug: Oral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate (MTX) monotherapy, 10 mg oral MTX weekly
Study: 37384482
Drug: Concurrent Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure
Study: 35842004
Drug: AZD5718 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5718 200 mg
Study: 35842004
Drug: AZD5718 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5718 50 mg
Study: 36284992
Drug: rosuvastatin, amlodipine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin, amlodipine, Ziyin Huoxue Recipe, and aspirin (experimental group)
Study: 33188208
Drug: Artificial nectar
Normalized name: Nectarine
DrugBank: Nectarine (DB10656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial nectar with added nicotine and anabasine (treatment)
Study: 32429733
Drug: Evervac vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evervac vaccine
Study: 32429733
Drug: TBE-Moscow vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBE-Moscow vaccine
Study: 33454782
Drug: European cooperation
Approvals — FDA: no, EMA: no, PMDA: no
Description: European cooperation packages with greater scope of medicines regulated
Study: 35476651
Drug: Nasal high-flow
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high-flow therapy
Study: 33992292
Drug: Music-based physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music-based physical therapy
Study: 35063953
Drug: As-needed low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: As-needed low-dose combination budesonide-formoterol
Study: 35063953
Drug: Maintenance inhaled
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance inhaled corticosteroids (ICS)
Study: 33389797
Drug: Lorcaserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin (10 mg BID)
Study: 35627855
Drug: Robotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic therapy (30 min)
Study: 35627855
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (30 min)
Study: 35093240
Drug: SY-004 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY-004 (2 mg)
Study: 35093240
Drug: SY-004 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY-004 (20 mg)
Study: 35093240
Drug: SY-004 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY-004 (40 mg)
Study: 35093240
Drug: SY-004 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY-004 (80 mg)
Study: 35093240
Drug: SY-004 (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY-004 (120 mg)
Study: 35093240
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 mg, 40 mg, 80 mg, 120 mg)
Study: 35093240
Drug: SY-004 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY-004 (all doses)
Study: 36109026
Drug: Telephone-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based cognitive behavioural therapy
Study: 35575067
Drug: WP1066 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WP1066 at 8 mg/kg
Study: 35575067
Drug: WP1066 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WP1066 at 1 mg/kg
Study: 33554636
Drug: Darolutamide and
Normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darolutamide and hormone therapy
Study: 33554636
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and hormone therapy
Study: 34393206
Drug: No medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medications
Study: 35227973
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: Orientation messages recorded in a non-family member's voice (10 min), reading a daily newspaper, wearing an eye patch at night
Study: 35227973
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: Orientation messages recorded in a family member's voice, reading a daily newspaper, wearing an eye patch at night
Study: 35051209
Drug: PC-6500 (0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC-6500 (0.1% GRFT in a carrageenan gel)
Study: 32918114
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment with FVIII/FIX
Study: 32918114
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment with FVIII/FIX in SHB
Study: 32918114
Drug: On-demand therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand therapy and hepatitis B and C
Study: 32787925
Drug: Self-administered therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered therapy (SAT)
Study: 33665997
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) 15 mg/kg intravenous drops before operation incision at 10 min
Study: 33665997
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (100 ml normal saline intravenous drops before operation incision at 10 min)
Study: 36267873
Drug: Sertraline for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline for 14 weeks
Study: 34516036
Drug: Learning Through
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Learning Through Play (LTP) plus Culturally adapted Cognitive Behaviour Therapy (CaCBT)
Study: 36442217
Drug: Premature infant
Normalized name: Premature infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premature infant oral motor intervention for five minutes twice a day along with routine care (n=16)
Study: 37855069
Drug: Deferasirox dispersible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox dispersible tablets (DT)
Study: 34431240
Drug: Vonoprazan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan (20 mg) after overnight fast
Study: 34431240
Drug: Vonoprazan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan (20 mg) after high-fat breakfast
Study: 36328438
Drug: Quadrivalent inactivated
Normalized name: Fluarix Quadrivalent 2018-2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent inactivated influenza vaccine
Study: 35460410
Drug: Pharmacist-led intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led intervention using validated tools to detect signs and symptoms of medicine-induced deterioration every 8 weeks over 12 months
Study: 35460410
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (Residential Medication Management Review) provided by accredited pharmacists
Study: 32039559
Drug: Low-dose CNI
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CNI plus costimulation blockade (belatacept) with intended CNI withdrawal
Study: 33499719
Drug: Parent Attitudes
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent Attitudes about Childhood Vaccines (PACV) survey
Study: 36496124
Drug: Intravenous analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous analgesia (Control)
Study: 33159633
Drug: Sequential tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential tamoxifen → letrozole
Study: 33159633
Drug: Sequential letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential letrozole → tamoxifen
Study: 34193518
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (immobilisation, analgesics, spinal orthoses)
Study: 33515378
Drug: Acetic acid
Normalized name: Acetic acid
DrugBank: Acetic acid (DB03166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetic acid (AA) solution (0.005%) irrigated by a water pump
Study: 33295220
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous ketamine infusion (0.5 mg/kg bolus at induction, 0.25 mg/kg/h during surgery)
Study: 33295220
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous ketamine infusion
Study: 34774810
Drug: Waitlist Treatment-as-usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist Treatment-as-usual
Study: 33180098
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 injection (1000 μg of cyanocobalamin)
Study: 33180098
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 injection
Study: 33180098
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 injection and Placebo
Study: 35670659
Drug: Daily titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily titration of iGlarLixi (1 unit/day)
Study: 35670659
Drug: Weekly titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly titration of iGlarLixi (2 or 4 units/week)
Study: 33749539
Drug: CHO mouth
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO mouth rinse (6.4% maltodextrin = 1.6 g)
Study: 33749539
Drug: CAF mouth
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF mouth rinse (1.2% caffeine = 300 mg)
Study: 33860732
Drug: New Zealand
Normalized name: NEW ZEALAND GREEN MUSSEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Zealand blackcurrant (NZBC) powder (6 g/day for 7 days, with 138.6 mg anthocyanins)
Study: 32838616
Drug: OD-evening 80
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: OD-evening 80 mg aspirin
Study: 32838616
Drug: BID 40
Normalized name: Lorabid 400mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID 40 mg aspirin
Study: 32838616
Drug: OD-morning 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: OD-morning 80 mg aspirin
Study: 34995804
Drug: Carbohydrate loading
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate loading with individualized supplemental insulin
Study: 35751892
Drug: Liraglutide plus
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide plus dapagliflozin (0.6 mg liraglutide and 5 mg dapagliflozin once a day)
Study: 33969592
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg, daily)
Study: 32598387
Drug: Drospirenone (DRSP)
Normalized name: Drospirenone
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drospirenone (DRSP) 4 mg for 24 days followed by 4 days of placebo
Study: 32598387
Drug: Desogestrel (DSG)
Normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desogestrel (DSG) 0.075 mg per day continuously
Study: 35794811
Drug: Home-based vestibular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based vestibular rehabilitation therapy (Bal Ex)
Study: 35794811
Drug: Hospital-based vestibular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital-based vestibular rehabilitation therapy (control)
Study: 33790161
Drug: Gemcitabine (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1,000 mg/m2) and Cisplatin (40 mg/m2) on days 1 and 15, and Bevacizumab (15 mg/kg) on day 1, repeated every 4 weeks
Study: 33790161
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus Cisplatin plus Bevacizumab combination chemotherapy
Study: 33225971
Drug: Nasal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high flow (NHF) at 1.5 L/kg PBW/min (75–120 L/min)
Study: 34641896
Drug: Direct-acting antiviral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antiviral (DAA) treatment
Study: 34800819
Drug: OJ (orange
Approvals — FDA: no, EMA: no, PMDA: no
Description: OJ (orange juice containing 345 mg of hesperidin; n=15)
Study: 34800819
Drug: EOJ (enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: EOJ (enhanced orange juice containing 600 mg of hesperidin; n=11)
Study: 32633157
Drug: Everolimus with
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus with reduced calcineurin inhibitor (EVR+rCNI)
Study: 34358497
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg and lamivudine 300 mg once daily
Study: 32331737
Drug: Natural ointment
Normalized name: Boudreauxs Butt Paste Natural Ointment
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Natural ointment based on honey-tea tree oil
Study: 35533197
Drug: Glutamate infusion
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glutamate infusion
Study: 36791792
Drug: Risperidone treatment
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone treatment
Study: 34653814
Drug: Endometrial scratching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrial scratching (twice endometrial sampling in follicular and luteal phases)
Study: 33327326
Drug: Peony and
Normalized name: DEXPANTHENOL 0.2 g in 100 mL / SALICYLIC ACID 0.2 g in 100 mL / NIACINAMIDE 0.1 g in 100 mL TOPICAL SHAMPOO [CH6 Perfumed Aloforthya Peony and the sunset]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peony and licorice decoction (PLD) fumigation treatment
Study: 33327326
Drug: Placebo fumigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo fumigation treatment
Study: 33327326
Drug: PLD fumigation
Normalized name: pLDLR-Neo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD fumigation treatment
Study: 35654684
Drug: Vasopressin injection
Normalized name: Vasopressin Injection
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin injection
Study: 33377451
Drug: Low-dose corticosteroids
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose corticosteroids
Study: 33906081
Drug: kMCT (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: kMCT (30 g/day)
Study: 33123219
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment for 12 months
Study: 34942085
Drug: Tezacaftor 100
Normalized name: tezacaftor 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezacaftor 100 mg orally once daily plus ivacaftor 150 mg orally every 12 h
Study: 34077535
Drug: NRT +
Normalized name: Nicotine Replacement Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRT + prescription medication
Study: 32725447
Drug: Scapular-focused treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scapular-focused treatment with feedback (SFTF)
Study: 32725447
Drug: Scapular-focused treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scapular-focused treatment without feedback (SFT)
Study: 32699034
Drug: Belimumab 10
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab 10 mg/kg intravenous every 4 weeks
Study: 34913216
Drug: Paper voucher
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper voucher described as redeemable for free follow-up and prescription glasses
Study: 34913216
Drug: Standard referral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard referral for a free follow-up appointment and prescription glasses
Study: 33731062
Drug: Active study
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active study product (combination of Bifidobacterium breve M‐16V, short‐chain galacto‐oligosaccharides, long‐chain fructo‐oligosaccharides and L‐glutamine)
Study: 39110421
Drug: Standard therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapies
Study: 34242463
Drug: Treatment Access
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Access Pathway (TAP)
Study: 32575450
Drug: Bioactive compounds
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioactive compounds (shaftoside, iso‐orientin, and orientin)
Study: 33191527
Drug: High-glucose mixed-nutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-glucose mixed-nutrient meal ingestion (1.1 g glucose/kg body weight; 45% carbohydrate, 20% protein, 35% fat)
Study: 33271093
Drug: HPV 16/18
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV 16/18 AS04‐adjuvanted vaccine
Study: 36170326
Drug: Oral amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amino acid challenge (AAC)
Study: 36170326
Drug: Isocaloric glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric glucose solution (GS)
Study: 39229259
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of IIV4 and PPV23
Study: 34607600
Drug: Oral immunomodulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunomodulation with UTI-relevant Escherichia coli lysate (Uro-Vaxom) for 90 days
Study: 35718535
Drug: Acitretin Capsules
Normalized name: Acitretin Capsules
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acitretin Capsules and Calcipotriol Ointment